CRL
$140.97
Charles River Laboratories Intl
$2.08
1.50%
CRL
Earnings Whisper ®
N/A
2nd Quarter June 2025
Consensus:  $2.47
Revenue:  $954.34 Mil
Wednesday
Aug 6
7:00 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when CRL reports earnings?
Beat
Meet
Miss

Where is CRL's stock price going from here?
Up
Flat
Down
Stock chart of CRL
Analysts
Summary of analysts' recommendations for CRL
Score
Grade
Pivots
Resistance
$148.07
$145.33
$143.15

$140.42

Support
$138.24
$135.50
$133.32
Tweet
Growth
Description
Charles River Laboratories International, Inc. is a full service, early-stage contract research organization. The company provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions globally accelerate their research and drug development efforts. The company has a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP. This helps support its clients from target identification through non-clinical development. Charles River also provides a line of products and services to support clients' manufacturing activities. Utilizing the company's broad portfolio of products and services, clients can create a more flexible drug development model, aiming cost reduction, productivity enhancement and increase in speed to market. Charles River currently has three reporting segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA) and Manufacturing Support.
Peers
Exact SciencesIncyteExelixisCoherus Biosciences